Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immatics N.V. - Ordinary Shares (NQ:IMTX)

9.840 +0.240 (+2.50%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Immatics N.V. - Ordinary Shares

< Previous 1 2 3 4 Next >
News headline image
Immatics Announces First Bristol Myers Squibb Opt-in of TCR-T Candidate from Ongoing Multi-target Strategic Collaboration
From https://immatics.com/
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2023 ↗
 
Via Benzinga
News headline image
Immatics Announces Full Year 2022 Financial Results and Corporate Update
From https://immatics.com/
Via GlobeNewswire
News headline image
Immatics Immunotherapy Candidate Shows Confirmed Responses In Different Solid Cancers ↗
 
Via Benzinga
News headline image
Immatics: Q2 Earnings Insights ↗
  Immatics (NASDAQ:IMTX) reported its Q2 earnings results on Tuesday, August 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
First Majestic Silver, Immatics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
U.S. stock futures traded higher this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Immatics Announces Third Quarter 2022 Financial Results and Business Update
From https://immatics.com/
Via GlobeNewswire
News headline image
Alphatec Holdings, Immatics And Some Other Big Stocks Moving Higher On Monday ↗
U.S. stocks traded lower, with the Dow Jones dropping more than 100 points on Monday. Here are some big stocks recording gained in today’s session. 
Via Benzinga
News headline image
Why Immunic Shares Jumped By Around 57%; Here Are 73 Biggest Movers From Yesterday ↗
Gainers Applied DNA Sciences, Inc. (NASDAQ: APDN) shares climbed 71% to close at $2.12 on Monday after the company announced it has received its largest single purchase order for LinearDNA™ valued... 
Via Benzinga
News headline image
Why Is Nutex Health (NUTX) Stock on the Move Today? ↗
Nutex Health (NUTX) stock is moving on Monday after the healthcare management company released a corporate update to investors. 
Via InvestorPlace
News headline image
Why Applied DNA Sciences Shares Are Trading Higher By Around 65%, Here Are 54 Stocks Moving In Monday's Mid-Day Session ↗
Gainers Applied DNA Sciences, Inc. (NASDAQ: APDN) shares jumped 64.5% to $2.03 after the company announced it has received its largest single purchase order for LinearDNA™ valued above the... 
Via Benzinga
News headline image
Ford Stock Slumps 7% on Analyst Downgrade ↗
Ford (F) stock is losing traction on Monday after UBS analyst Patrick Hummel hit the automobile company's shares with a downgrade. 
Via InvestorPlace
News headline image
Why Is Immatics (IMTX) Stock Up 7% Today? ↗
Immatics (IMTX) stock is climbing higher on Monday after the biopharmaceutical company revealed an underwritten public offering. 
Via InvestorPlace
News headline image
Immatics Announces $110 Million Underwritten Offering of Ordinary Shares
From https://immatics.com/
Via GlobeNewswire
News headline image
Immatics Reports Interim Clinical Data Update on ACTengine® IMA203 TCR-T Monotherapy Targeting PRAME
From https://immatics.com/
Via GlobeNewswire
News headline image
Why Tuesday Morning Shares Tumbled 31%; Here Are 66 Biggest Movers From Yesterday ↗
Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 101.3% to settle at $0.5558 on Monday after the company announced a 1-for-30 reverse stock split. 
Via Benzinga
News headline image
Why Ventyx Biosciences Is Trading Higher By 70%, Here Are 46 Stocks Moving In Monday's Mid-Day Session ↗
Gainers Ventyx Biosciences, Inc. (NASDAQ: VTYX) shares jumped 70.4% to $39.37 after Oppenheimer maintained an Outperform rating on the stock and raised its price target from $40 to $65. 
Via Benzinga
News headline image
Livent, Amgen And Some Other Big Stocks Moving Lower On Monday ↗
U.S. stocks traded higher, with the Dow Jones gaining more than 250 points on Monday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
News headline image
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary ↗
 
Via Benzinga
News headline image
Why Is CarLotz Higher By More Than 30%: Here Are 28 Stocks Moving Premarket ↗
Gainers ObsEva SA (NASDAQ: OBSV) shares rose 33.8% to $0.4080 in pre-market trading. ObsEva recently announced a $31 million debt retirement and $11 million debt refinancing. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
  
Via Benzinga
News headline image
Why Crypto-Related Companies Traded Higher; Here Are 72 Biggest Movers From Yesterday ↗
Gainers Applied Blockchain, Inc. (NASDAQ: APLD) shares climbed 100% to close at $2.12 on Tuesday after the company reported a 200-megawatt five-year hosting contract with Marathon Digital Holdings and... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
  
Via Benzinga
News headline image
UnitedHealth, Shockwave Lead 5 Healthy Stocks Breaking Out Or Setting Up ↗
Shockwave and UnitedHealth lead 5 stocks that are setting up or breaking out. 
Via Investor's Business Daily
News headline image
The Daily Biotech Pulse: Veru Seeks Emergency Use Nod For COVID-19 Therapy, Vincerx Cuts Workforce, Moderna Starts Dosing In Flu Vaccine Study ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs
From Bristol Myers Squibb
Via Business Wire
News headline image
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Immatics Initiates Phase 1 Clinical Trial of IMA401 in Advanced Solid Tumors ↗
Immatics N.V. (NASDAQ: IMTX) announced the initiation of a Phase 1 clinical trial of its drug candidate IMA401 for patients with recurrent and/or refractory solid tumors. 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.